Sanofi-aventis (NYSE: SNY) and Bristol-Myers Squibb Company (NYSE: BMY) announced today that the American Heart Journal published the rationale and design of the ongoing CURRENT-OASIS 7 trial, a study evaluating the effects of standard and higher-dosing regimens of Plavix® (clopidogrel bisulfate) and aspirin on cardiovascular outcomes and bleeding complications in patients with acute coronary syndrome (ACS) who are intended to undergo intervention with coronary angioplasty.

More: continued here

This entry was posted on Friday, November 7th, 2008 at 1:11 pm and is filed under Blood. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.